Overview

The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2027-12-31

Target enrollment:

Participant gender:

Summary

To confirm the tolerability and safety of combined administration of ONO-7913, ONO-4538 and the standard of care FOLFOX in combination with bevacizumab or cetuximab as first-line treatment in patients with unresectable advanced or recurrent colorectal cancer

Phase:

PHASE1

Details

Lead Sponsor:

Ono Pharmaceutical Co. Ltd

Treatments:

Bevacizumab
Cetuximab
Fluorouracil
Leucovorin
magrolimab
Nivolumab
Oxaliplatin